Triple-negative breast cancer (TNBC) is one of the main tumor subtypes of BC, which lacks the expression of hormone receptors (estrogen/progesterone, ER/PR) and human epidermal growth factor receptor 2 (HER2) amplification, leading to a lack of effective treatment against the corresponding targets or receptors in addition to chemotherapy and radiotherapy. This evidence concerns the gene ERBB2 and neoplasm.